CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Lucero develops a novel platform that integrates microfluidics, optical tweezers, and artificial intelligence to enhance drug screening. This technology enables the selective handling of patient-derived 3D cell cultures, improving the prediction of drug effects and facilitating personalized medicine in the pharmaceutic…
Personalised medicine has become a key focus for the pharmaceutical industry as it can address global health challenges, such asstrong variations of drug efficacy and toxicity linked to different patient subgroups. A major obstacle that pharmaceutical companies still face is the lack of enabling technologies to predict the effects of drug candidates in patients before entering clinical trials.
In preclinical drug screening procedures, pharmaceutical companies demand that the technologies be sele…
Lucero AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
